Navigation Links
Intercept Pharmaceuticals Names Dr. Luciano Adorini Chief Scientific Officer
Date:1/3/2008

NEW YORK, Jan. 3 /PRNewswire/-- Intercept Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing therapeutics for the treatment of chronic fibrotic and metabolic diseases, today announced the appointment of Luciano Adorini, M.D., to the newly created position of Chief Scientific Officer. Dr. Adorini brings over 20 years of experience in therapeutic research and development, recently serving as Chief Scientific Officer at BioXell (SWX: BXLN), a biopharmaceutical company which he co-founded.

Mark Pruzanski, M.D., Founder, President and CEO of Intercept Pharmaceuticals, commented, "Luciano's proven R&D leadership will be invaluable as we continue to advance our pipeline of first-in-class compounds and expand our focus beyond chronic liver diseases to other indications involving progressive organ damage that results from some combination of chronic inflammation, fibrosis and metabolic dysfunction."

During Dr. Adorini's tenure at BioXell, he was responsible for advancing a broad pipeline of products in multiple disease indications. Prior to this, he served as Associate Director of Roche Milano Ricerche, where he contributed to the development of several drugs. Earlier in his career, Dr. Adorini was research director of a unit at the Preclinical Research Center, Sandoz Pharma, Ltd., in Basel.

Dr. Adorini has authored over 240 journal articles and other scientific publications, becoming a highly cited researcher in Immunology, with a focus on immunosuppressive and immunoregulatory mechanisms in the treatment of inflammatory and autoimmune diseases. He is a board member of a number of peer-reviewed publications and is currently serving as president of the Italian Society of Immunology, Clinical Immunology and Allergology. Dr. Adorini received his M.D. degree from the Medical School of Padova University and conducted postdoctoral studies at the University of California at Los Angeles.

About Intercept Pharmaceuticals

New York City-based Intercept Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing small molecule drugs for the treatment of chronic liver and metabolic diseases. Since 2002, Intercept researchers have published extensively on the key role of the farnesoid X receptor (FXR) as a regulator of bile and cholesterol metabolism in the liver, with preclinical data from numerous studies providing strong rationale for the advancement of FXR agonists as hepatoprotective therapeutics in chronic liver disease. The Company intends to lead in the advancement of drug candidates acting on FXR and other bile acid receptors and is developing a pipeline of novel lead compounds for multiple indications. For more information on Intercept Pharmaceuticals, please visit the Company's website at http://www.interceptpharma.com .


'/>"/>
SOURCE Intercept Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2017)... ... August 23, 2017 , ... NDA Partners Chairman Carl ... the Office of Device Evaluation at the FDA’s Center for Devices and Radiological Health ... firm as an Expert Consultant. , Prior to his FDA experience, Dr. Sheets served ...
(Date:8/21/2017)... ... August 20, 2017 , ... Brian Pogue of Dartmouth ... January 2018. The journal is published by SPIE, the international society for optics ... of modern optical technology for improved health care and biomedical research. The journal ...
(Date:8/21/2017)... , ... August 21, 2017 , ... ... two speakers for this two-part educational webinar, in which attendees will learn about ... associated protein factor composition. Along with an overview of the development and validation ...
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... ... cancer research and personalized medicine, today announced the launch of a new breast ... Missouri. The study’s goal is to evaluate the potential for early detection of ...
Breaking Biology Technology:
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities ... (physiological and behavioral), by technology (fingerprint, AFIS, iris recognition, ... recognition, and others), by end use industry (government and ... immigration, financial and banking, and others), and by region ... , Asia Pacific , and ...
(Date:3/27/2017)... N.Y. , March 27, 2017  Catholic ... Information and Management Systems Society (HIMSS) Analytics for ... EMR Adoption Model sm . In addition, CHS ... of U.S. hospitals using an electronic medical record ... for its high level of EMR usage in ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by ... Global Forecast to 2022", published by MarketsandMarkets, the market is expected to be ... 2017 and 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):